Sarep­ta to col­lab­o­rate with Genethon on DMD gene ther­a­py; Chi­nese in­vestors pull back on Pluris­tem in­vest­ment

→ Cam­bridge, MA-based Sarep­ta $SRPT is dou­bling down on new work fo­cused on de­vel­op­ing a gene ther­a­py for Duchenne mus­cu­lar dy­s­tro­phy. The biotech inked …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA